Skip to search formSkip to main contentSkip to account menu

piperacillin-tazobactam combination

Known as: Piperacillin+Tazobactam, piperacillin-tazobactam combination product, Piperacillin-Tazobactam 
A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a… 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (3)

Anti-Bacterial AgentsPenicillanic Acidbeta-Lactamase Inhibitors
PiperacillinPiperacillin 3000 MG / tazobactam 375 MG InjectionPiperacillin 4000 MG / tazobactam 500 MG InjectionPiperacillin+Tazobactam:Susc:Pt:Isolate:OrdQn

Narrower (2)

Zosyntazocillin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Highly Cited
2009
Highly Cited
2009
MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Highly Cited
2009
Highly Cited
2009
β-Lactam Resistance in Salmonella Strains Isolated from Retail Meats in the United States by the National Antimicrobial Resistance Monitoring System between 2002 and 2006
ABSTRACT Ampicillin-resistant (Ampr) Salmonella enterica isolates (n = 344) representing 32 serotypes isolated from retail meats… 
2005
2005
Bacteremia in patients with hematological malignancies.
BACKGROUND An appropriate regimen in the empirical therapy of neutropenic fever episodes must be individualized at each… 
Highly Cited
2003
Highly Cited
2003
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
Highly Cited
2002
Highly Cited
2002
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Highly Cited
2002
Highly Cited
2002
Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000.
Highly Cited
2001
Highly Cited
2001
In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia
ABSTRACT Ertapenem (MK-0826, L-749,345) is a 1-β-methyl carbapenem with a long serum half-life. Its in vitro activity was… 
Review
2000
Review
2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) is a global, multicentre surveillance study that… 
Highly Cited
2000
Highly Cited
2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types.
The activity of meropenem and five comparators has been studied against 7886 isolates from 29 centres in 10 European countries… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)